- Home
- ANVS vs TIL Comparison
ANVS vs TIL Comparison
Compare ANVS & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | TIL |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 74.7M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANVS | TIL |
|---|---|---|
| Price | $1.99 | $7.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $13.50 | ★ $125.00 |
| AVG Volume (30 Days) | ★ 359.7K | 18.8K |
| Earning Date | 03-16-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $5.67 |
| 52 Week High | $5.50 | $42.75 |
Technical Indicators
Market Signals| Indicator | ANVS | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 38.26 |
| Support Level | $1.97 | $6.85 |
| Resistance Level | $2.99 | $9.05 |
| Average True Range (ATR) | 0.22 | 0.45 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 1.89 | 13.62 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.